Table 3.
Comparison of clinical and laboratory features according to BVAS.
| Patients with low BVAS (N = 37) | Patients with high BVAS (N = 38) | p value | |
|---|---|---|---|
| Variants (N (%)) | 0.264 | ||
| MPA | 16 (43.2%) | 22 (57.9%) | |
| GPA | 12 (32.4%) | 9 (23.7%) | |
| EGPA | 9 (24.3%) | 7 (18.4%) | |
| Demographic data | |||
| Age (years) | 59.7 ± 13.2 | 58.1 ± 16.8 | 0.644 |
| Male gender (N (%)) | 11 (29.7%) | 15 (39.5%) | 0.379 |
| Disease duration (months) | 29.7 ± 37.0 | 6.9 ± 21.8 | 0.002 |
| AAV-specific indices | |||
| BVAS | 4.0 ± 1.9 | 15.1 ± 5.2 | <0.001 |
| FFS (2009) | 1.2 ± 0.8 | 1.4 ± 1.0 | 0.221 |
| VDI | 3.0 ± 1.9 | 3.4 ± 1.6 | 0.263 |
| SF-36 PCS score | 57.4 ± 23.2 | 42.6 ± 21.3 | 0.005 |
| SF-36 MCS score | 61.8 ± 20.0 | 52.0 ± 22.1 | 0.048 |
| Clinical manifestations (N (%)) | |||
| General | 6 (16.2%) | 20 (52.6%) | 0.001 |
| Cutaneous | 3 (8.1%) | 6 (15.8%) | 0.480 |
| Mucous membrane and eye | 1 (2.7%) | 4 (10.5%) | 0.358 |
| Ear, nose, and throat | 16 (43.2%) | 19 (50.0%) | 0.560 |
| Pulmonary | 19 (51.4%) | 29 (76.3%) | 0.025 |
| Cardiovascular | 2 (5.4%) | 3 (7.9%) | 0.999 |
| Abdominal | 0 (0.0%) | 0 (0.0%) | N/A |
| Renal | 13 (35.1%) | 25 (65.8%) | 0.008 |
| Nervous system | 8 (21.6%) | 8 (21.1%) | 0.952 |
| ANCA positivity (N (%)) | |||
| P-ANCA | 16 (43.2%) | 25 (65.8%) | 0.051 |
| C-ANCA | 2 (5.4%) | 5 (13.2%) | 0.430 |
| MPO-ANCA | 13 (35.1%) | 24 (63.2%) | 0.016 |
| PR3-ANCA | 1 (2.7%) | 5 (13.2%) | 0.200 |
| ANCA positivity | 19 (51.4%) | 30 (78.9%) | 0.013 |
| Laboratory data | |||
| WBC count (/mm3) | 7.5 ± 3.4 | 10.4 ± 4.9 | 0.004 |
| Hemoglobin (g/dL) | 12.6 ± 1.8 | 10.7 ± 2.6 | <0.001 |
| Platelet count (×1000/mm3) | 256.8 ± 76.7 | 348.7 ± 173.5 | 0.004 |
| Blood urea nitrogen (mg/dL) | 19.5 ± 10.3 | 29.9 ± 20.0 | 0.006 |
| Creatinine (mg/dL) | 1.2 ± 1.1 | 2.3 ± 2.1 | 0.008 |
| Total protein (g/dL) | 6.6 ± 0.6 | 6.1 ± 0.7 | 0.004 |
| Serum albumin (g/dL) | 4.0 ± 0.4 | 3.2 ± 0.6 | <0.001 |
| AST (IU/L) | 21.4 ± 14.0 | 19.9 ± 8.8 | 0.609 |
| ALT (IU/L) | 23.0 ± 20.2 | 25.7 ± 21.7 | 0.578 |
| ESR (mm/hr) | 31.4 ± 17.7 | 57.4 ± 39.6 | <0.001 |
| CRP (mg/L) | 3.8 ± 6.5 | 34.5 ± 51.5 | <0.001 |
| SAA (ng/mL) | 423.1 ± 481.8 | 1317.1 ± 854.7 | <0.001 |
Values are expressed as mean ± standard deviation or number (percentage). BVAS: Birmingham Vasculitis Activity Score; MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; FFS: five-factor score; VDI: vasculitis damage index; SF-36: Short-Form 36-Item Health Survey; PCS: physical component summary; MCS: mental component summary; N/A: not applicable; P: perinuclear; C: cytoplasmic; MPO: myeloperoxidase; PR3: proteinase 3; WBC: white blood cell; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SAA: serum amyloid A.